002437 Harbin Gloria Pharmaceuticals
- 2.74
- 0.000.00%
Harbin Gloria Pharmaceuticals News
Express News | This week, more than 20 listed companies disclosed the repurchase and shareholding related information. Pingdingshan Tianan Coal Mining plans to repurchase special loans not exceeding 0.7 billion yuan.
Express News | Harbin Gloria Pharmaceuticals: Received the "Loan Commitment Letter" and obtained special financing support for repurchasing company shares.
Yuheng Pharmaceutical: Report for the third quarter of 2024
A-share market anomaly | Planning to repurchase shares, harbin gloria pharmaceuticals once rose more than 7%.
Gelonghui October 22 | Harbin Gloria Pharmaceuticals (002437.SZ) rose more than 7% at the opening, now trading at 2.26 yuan, with a total market value of 5.15 billion yuan. The company announced after the market yesterday that, based on confidence in the company's future continuous development and recognition of the company's value, it plans to repurchase shares with 50 million yuan to -0.1 billion yuan. The company believes that through this share buyback activity, it will not only effectively enhance the EPS level and strengthen the intrinsic value of the enterprise, but also greatly inspire all employees' enthusiasm and creativity, jointly promote the company towards new glory. In addition, this is also beneficial for maintaining price stability in the secondary market, protecting the
Express News | Harbin Gloria Pharmaceuticals: plans to repurchase shares for 50 million yuan to -0.1 billion yuan.
Express News | Harbin Gloria Pharmaceuticals: Director Wang Dongxu plans to reduce shareholding by no more than 0.0092% of the company's shares.
Harbin Gloria Pharmaceuticals (002437.SZ): The largest shareholder and acting in concert have collectively increased their shareholding by 1%.
On September 13, GeLongHui announced that Harbin Gloria Pharmaceuticals (002437.SZ) received a "Notice Letter" from Shen Zhenyu and Shanghai Fangyuan Capital Investment Partnership Enterprise (Limited Partnership) ("Shanghai Fangyuan"), and learned that from February 20, 2024 to September 13, 2024, Shanghai Fangyuan increased its shareholding in the company by 12.7751 million shares through the "Shanghai Fangyuan Capital Investment Partnership Enterprise (Limited Partnership) - Fangyuan-Oriental No. 6 Private Equity Investment Fund" ("Fangyuan No. 6 Fund") and the "Shanghai Fangyuan Capital Investment Partnership Enterprise (Limited Partnership) - Fangyuan-Oriental No. 12
Harbin Gloria Pharmaceuticals (002437.SZ) granted a total of 11.41 million restricted stocks to 45 incentive recipients.
Harbin Gloria Pharmaceuticals (002437.SZ) announced that the restrictions stipulated in the company's 2024 restricted stock incentive plan...
Harbin Gloria Pharmaceuticals: Half-year report for the year 2024.
Harbin Gloria Pharmaceuticals: Summary of Half-Year Report in 2024.
Harbin Gloria Pharmaceuticals (002437.SZ): Net income of 0.12 billion yuan in the first half of the year, a year-on-year increase of 342.39%.
Harbin Gloria Pharmaceuticals (002437.SZ) released its semi-annual report on August 23. The revenue was 1.221 billion yuan, a decrease of 14.75% compared to the same period last year. The net income was 0.12 billion yuan, an increase of 342.39% compared to the same period last year. The non-GAAP net income was 94.15 million yuan, an increase of 251.66% compared to the same period last year. The basic earnings per share was 0.0556 yuan.
Express News | Harbin Gloria Pharmaceuticals received a warning letter due to inaccurate performance forecasts.
As of August 9, 2024, Harbin Gloria Pharmaceuticals (002437.SZ) has a total of approximately 0.0985 million shareholders.
Harbin Gloria Pharmaceuticals (002437.SZ) stated on the investor communication platform on August 15th that as of August 9th, 2024, the total number of company shareholders was approximately 0.0985 million.
Harbin Gloria Pharmaceuticals (002437.SZ): As of July 31, the total number of shareholders of the company is about 0.0971 million households.
On August 5th, Gloria Pharmaceuticals (002437.SZ) stated on the investor interaction platform that as of July 31st, the total number of shareholders in the company was approximately 0.0971 million households.
Harbin Gloria Pharmaceuticals (002437.SZ): There is not much pressure on the centralized procurement of the company's core products in the second half of the year.
On July 9th, Gelunhui reported that Harbin Gloria Pharmaceuticals (002437.SZ) stated during a recent investor visit to institutions that the company's main products, including Deer Antler Polypeptide Injection, Potassium Chloride Sustained-Release Tablets (Budexiu), and various vitamins (12) for injection, have already been included in centralized procurement. An Nao Wan/Pian does not yet meet the conditions for centralized procurement. In the second half of the year, the company's core products face little pressure from centralized procurement.
Harbin Gloria Pharmaceuticals (002437.SZ): The target audience of potassium chloride sustained-release tablets (Budexiu) is mainly patients with hypokalemia.
Harbin Gloria Pharmaceuticals (002437.SZ) recently stated during a reception for institutional investors that the target audience of their sustained-release potassium chloride tablets (Budaxiu) mainly includes patients with hypokalemia, some patients with cardiovascular and cerebrovascular diseases, and people who need fluid replacement due to excessive sweating. The product is also effective in preventing hypokalemia. Budaxiu is a national essential drug and included in the National Medical Insurance Catalogue. It has a sales history of more than 30 years, and a high brand recognition and reputation. The company is the first in the country to pass the consistency evaluation of sustained-release potassium chloride tablets. After being selected in the fifth batch of national drug centralized procurement in 2021, the medical institution coverage rate and sales volume of this product have increased.
Harbin Gloria Pharmaceuticals (002437.SZ): Currently promoting first and third joint products are cardiovascular and cerebrovascular drugs.
Harbin Gloria Pharmaceuticals (002437.SZ) recently stated during a reception for institutional investors that the company has been cooperating with Daiichi Sankyo since 2015. The two parties have had a good cooperative relationship for nearly 10 years, and the cooperation is stable. Currently, the Daiichi Sankyo products promoted by the company are all cardiovascular and cerebrovascular drugs.
Express News | There is a significant difference between performance forecasts and annual report data that has not been corrected in a timely manner, and Harbin Gloria Pharmaceuticals and its directors have received a regulatory letter from the Shenzhen Stock Exchange.
Harbin Gloria Pharmaceuticals (002437.SZ): Holds a market share of over 80% for injectable multivitamins (12) by Pude Pharmaceutical.
On July 5th, 2024, Harbin Gloria Pharmaceuticals (002437.SZ) accepted a specific survey and was asked about the market competitiveness and barriers of multiple vitamin (12) injections. The company replied that currently, there are only two companies selling this product in the market, and the market share of multiple vitamin (12) injections by Pude Pharmaceutical exceeds 80%. The market for this product is large and the difficulty of imitation is high. It is expected that the market structure will be relatively stable in the next 2-3 years.
Harbin Gloria Pharmaceuticals (002437.SZ): PuDe Pharma has signed more than 100 CMO business products in total, and future CMO business will move closer to the research and development end.
On July 5th, 2024, Harbin Gloria Pharmaceuticals (002437.SZ) accepted a specific object investigation regarding "What is the business volume of CMO and the layout of CDMO?" The company replied that Pude Pharmaceutical is a well-known injection contract manufacturer in the north, and has signed more than 100 CMO businesses for products. With these products successively approved, listed, and sold, it is expected to contribute revenue and profits to the company. In the future, the company's CMO business will move closer to the research and development end, striving to produce better products. The company has collaborated with Nanjing Biomaker on equity+product cooperation, as well as conducting other business with CRO enterprises.
Analysis
Price Target
No Data
No Data